Ericka Wiebe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ericka Wiebe has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
A. Menon
Department of Oncology, University of Alberta, Edmonton, Alberta, Canada
1 shared publication- Alina Sturdza
Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria
1 shared publication - Ananya Beruar
Division of Radiation Oncology, Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Cross Cancer Institute, 11560 University Avenue NW, Edmonton, AB T6G 1Z2, Canada
1 shared publication - Astrid De Leeuw
Department of Radiation Oncology, University Medical Centre Utrecht, 3584 CX Utrecht, The Netherlands
1 shared publication B. Murray
Department of Oncology, University of Alberta, Edmonton, Alberta, Canada
1 shared publication- Barbara Segedin
Department of Radiotherapy, Institute of Oncology Ljubljana and Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia
1 shared publication
Latest Publications
- Open Access
- 28 May 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (6) , 317
Endometrial Cancer Recurrence Risk Following Robotic Hysterectomy
Background: Minimally invasive surgery is widely used in endometrial cancer management, but recurrence remains a concern. Methods: A retrospective review of 1201 patients treated from 2012 to 2019 with robotic laparoscopy was conducted. Recurrence-free survival and hazard ratios were calculated using multivariate Cox models. Results: Of 1278 patients, 155 cases of recurrent disease were identified. Age (HR 1.01, p = 0.045), LVSI (HR 3.54, p < 0.001), stage and high-grade histology (HR 3.39, p < 0.001) were associated with increased risk of recurrence. Hazard ratios for stages IB, II and III/IV were 1.92 (p = 0.007), 2.67 (p = 0.001), and 3.23 (p < 0.001) respectively. The use of a uterine manipulator was an independent risk factor on multivariate analysis (HR 2.12, p < 0.001). Adjuvant chemotherapy (HR 0.67, p = 0.239) and radiotherapy (HR 0.64, p = 0.056) trends favored reduced risk but were not significant. Chemoradiotherapy was found to have a reduction in recurrence with a HR 0.44 (p = 0.002). Conclusions: Traditional prognostic factors remain important for patients with endometrial cancer having undergone robotic laparoscopic hysterectomy. Uterine manipulator use should be carefully reconsidered in endometrial cancer surgery.
- 28 May 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (6) , 317
Open AccessEndometrial Cancer Recurrence Risk Following Robotic Hysterectomy
Background: Minimally invasive surgery is widely used in endometrial cancer management, but recurrence remains a concern. Methods: A retrospective review of 1201 patients treated from 2012 to 2019 with robotic laparoscopy was conducted. Recurrence-free survival and hazard ratios were calculated using multivariate Cox models. Results: Of 1278 patients, 155 cases of recurrent disease were identified. Age (HR 1.01, p = 0.045), LVSI (HR 3.54, p < 0.001), stage and high-grade histology (HR 3.39, p < 0.001) were associated with increased risk of recurrence. Hazard ratios for stages IB, II and III/IV were 1.92 (p = 0.007), 2.67 (p = 0.001), and 3.23 (p < 0.001) respectively. The use of a uterine manipulator was an independent risk factor on multivariate analysis (HR 2.12, p < 0.001). Adjuvant chemotherapy (HR 0.67, p = 0.239) and radiotherapy (HR 0.64, p = 0.056) trends favored reduced risk but were not significant. Chemoradiotherapy was found to have a reduction in recurrence with a HR 0.44 (p = 0.002). Conclusions: Traditional prognostic factors remain important for patients with endometrial cancer having undergone robotic laparoscopic hysterectomy. Uterine manipulator use should be carefully reconsidered in endometrial cancer surgery.
- Open Access
- 30 January 2023
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 181, 109501
Association of persistent morbidity after radiotherapy with quality of life in locally advanced cervical cancer survivors
- 30 January 2023
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 181, 109501
Open AccessAssociation of persistent morbidity after radiotherapy with quality of life in locally advanced cervical cancer survivors
- 21 September 2022
- Published by Elsevier in Clinical Oncology
- Vol. 35 (1) , e94-e102
Adjuvant Radiotherapy in Stage II Endometrial Cancer: Selective De-intensification of Adjuvant Treatment
- 21 September 2022
- Published by Elsevier in Clinical Oncology
- Vol. 35 (1) , e94-e102
Adjuvant Radiotherapy in Stage II Endometrial Cancer: Selective De-intensification of Adjuvant Treatment
- 16 October 2013
- Published by Springer Nature
- p. 185-196
Controversies in the Management of Advanced Vulvar Cancer
- 16 October 2013
- Published by Springer Nature
- p. 185-196
Controversies in the Management of Advanced Vulvar Cancer